RecruitingPhase 1NCT03541889

REVEAL Biomarkers of Engraftment After Alternative Donor HSCT

Multi-institutional Prospective Pilot Research of Imaging and Blood Biomarker EValuation of Engraftment After ALlogeneic Hematopoietic Stem Cell Transplantation


Sponsor

University of Oklahoma

Enrollment

50 participants

Start Date

Oct 21, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples to investigate whether the cells are growing well.


Eligibility

Min Age: 4 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called FLT imaging and TK1 blood measurements for people with primary graft failure. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 4 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFLT imaging and TK1 blood measurements

F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.


Locations(4)

Emory University

Atlanta, Georgia, United States

University of Michigan

Ann Arbor, Michigan, United States

University Hospital of Cleveland UH Seidman Cancer Center

Cleveland, Ohio, United States

University of Oklahoma Health Sciences Center, Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03541889


Related Trials